Enfusion — Q2 2023 Earnings Presentation
21 slides from Enfusion's earnings presentation, Aug 8, 2023
Slide 1: Enfusion 2Q 2023 Shareholder Letter
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. ©2023 ENFUSION. ALL RIGHTS RESERVED. Enfusion 2Q 2023 Shareholder Letter August 2023
Slide 2: Disclaimer: Forward-Looking Statements
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Disclaimer 2 Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933 (
Slide 3: Dear Shareholders
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 3 Dear Shareholders, I’m happy to report a balanced quarter on the top and bottom-line. As we have discussed in the past several quarters, we are witnessing signs of volatility in the financial markets that impact our customers. Durin
Slide 4: Our mission
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. To help solve investment managers’ evolving business and operational challenges through next generation technology Our mission 4
Slide 5: Simplify and unify the investment management lifecycle
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. …empowering teams to operate in concert CFO COO CIO Portfolio Manager Analysts Traders Compliance Officer Investor Relations Middle Office Back Office We simplify and unify the investment management lifecycle We manage complex workflo
Slide 6: Serving clients across the investment management industry
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 6 Serving clients across the investment management industry Alternative Investment Managers Hedge Funds Private Equity Private Credit Family Offices Institutional Investment Managers Wealth Managers Traditional Asset Managers Mutual F
Slide 7: Purpose-built end-to-end solution
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Purpose-built end-to-end solution 7 Portfolio Management System Order Execution Management System Technology-Powered Services Accounting / General Ledger Analytics • Live details of portfolio positions • Real-time Investment Book of R
Slide 8: Addressing a large and growing market
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Robust growth in Underlying industry Addressing a large and growing market $11.5bn $5.7bn $2.0bn $19bn+ Software & IT services from Investment Management Internal IT spend IT hardware spend Source: IDC’s Worldwide Capital Markets IT S
Slide 9: Client-centric approach: Why we win
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 9 Client-centric approach Why we win One end-to-end solution, one single dataset and source of truth Rapid pace of delivery and evolution Open, flexible and tailored Unique ability to lead with a single solution – and then adjust to a
Slide 10: Q2 2023 key financial highlights
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Q2 2023 key financial highlights $42.7 16.9% YoY Growth Adjusted Free Cash Flow Z00 Total Revenue Z00 Adjusted EBITDA Z00 47.8% FCF Conversion $3.8 $28.5 66.7% Gross Margin Highly attractive SaaS model with combination of scale, growt
Slide 11: Strong growth trends with ongoing profitability
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. $5.3 $5.4 $6.8 $5.7 $8.0 $2.6 $0.8 $4.7 $1.0 2Q22 3Q22 4Q22 1Q23 2Q23 Adjusted EBITDA Net Income Strong growth trends with ongoing profitability Operating Cash Flow and Adjusted Free Cash Flow $ in millions $36.5 $39.2 $40.5 $41.0 $42
Slide 12: Organic, sticky expansion at scale
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. $148.7 $158.7 $164.7 $167.0 $171.2 2Q22 3Q22 4Q22 1Q23 2Q23 121.9% 116.6% 115.4% 110.5% 106.1% 2Q22 3Q22 4Q22 1Q23 2Q23 Organic, sticky expansion at scale 12 Net Dollar Retention Rate(1) Avg Contract Value 793 810 819 813 827 2Q22 3Q2
Slide 13: Financial outlook
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Financial outlook 13 2023E Revenue $170 ̶ $175 million Adjusted EBITDA $30 $32 million ̶ These statements are forward-looking and actual results may differ materially. Refer to the “Forward-Looking Statements” safe harbor section belo
Slide 14: Appendix
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Appendix
Slide 15: Consolidated Balance Sheets
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 15 ENFUSION, INC. CONSOLIDATED BALANCE SHEETS (dollars in thousands, except par value) ASSETS Current assets: Cash and cash equivalents $ 27,771 $ 62,545 Accounts receivable, net 25,170 25,855 Prepaid expenses 4,967 6,105 Other curren
Slide 16: Consolidated Statements of Operations
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 16 ENFUSION. INC. CONSOLIDATED STATEMENTS OF OPERATIONS (dollars in thousands) (Unaudited) REVENUES: Platform subscriptions $ 39,610 $ 33,560 Managed services 2,945 2,396 Other 166 584 Total revenues 42,721 36,540 COST OF REVENUES: Pl
Slide 17: Consolidated Statements of Cash Flows
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 17 ENFUSION. INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (dollars in thousands) (Unaudited) Cash flows from operating activities : Net income (loss) $ 5,692 $ (16,649) Adjustments to reconcile net income (loss) to net cash provided by
Slide 18: Reconciliations to Non-GAAP Financial Measures
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Reconciliations To Non-GAAP Financial Measures 18 The following table reconciles net income to adjusted EBITDA: The following table reconciles gross profit to adjusted gross profit: ($ in thousands) June 30, 2022 September 30, 2022 De
Slide 19: Reconciliations to Non-GAAP Financial Measures
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. Reconciliations To Non-GAAP Financial Measures 19 The following table reconciles operating cash flow to adjusted free cash flow : The Company’s stock compensation expense was recognized in the following captions within the consolidate
Slide 20: Definitions
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 20 Definitions Non-GAAP Financial Measures In addition to financial measures prepared in accordance with GAAP, this presentation and the accompanying tables include Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit, Adjus
Slide 21: Definitions Continued
PROPRIETARY AND CONFIDENTIAL ©2023 ENFUSION. ALL RIGHTS RESERVED. 21 Definitions Continued Key Metrics: In connection with the management of our business, we identify, measure and assess a variety of key metrics. The key metrics we use in managing our business are set forth below. Annual Recurring R